BlueStar

By Heather Mack 12:35 pm January 19, 2017
The US Food and Drug Administration has given the green light for a non-prescription version of BlueStar, WellDoc’s mobile diabetes management platform. Through this 510(k) class II clearance, WellDoc will now offer BlueStar and BlueStar Rx, allowing the company to offer the product through more channels. Both versions analyze diabetes data entered by the patient, comparing past data trends to...
By Jonah Comstock 03:08 pm January 4, 2017
WellDoc announced today a partnership with the American Association of Diabetes Educators (AADE), a professional membership organization of over 14,000 diabetes educators. WellDoc will incorporate educational content from AADE into its FDA-cleared, reimburseable BlueStar system for diabetes management.  "We were able to build a curriculum that will be able to be delivered in a contextually guided...
By Heather Mack 02:47 am December 19, 2016
The FDA has cleared the wireless integration of one of Johnson and Johnson subsidiary LifeScan’s blood glucose monitoring systems and WellDoc’s digital diabetes management platform for people with type 2 diabetes. The two companies originally teamed up in March of this year. The integrated system consists of OneTouch Verio Flex, LifeScan’s Bluetooth smart blood glucose monitoring system and...
By Jonah Comstock 02:14 pm September 14, 2016
The partnership announced in March between Johnson & Johnson subsidiary LifeScan and diabetes management company WellDoc has entered a new stage with a commercial partnership agreement, the companies announced yesterday.  "We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson...
By Aditi Pai 09:51 am March 1, 2016
Baltimore, Maryland-based WellDoc has announced a collaboration with LifeScan, a Johnson and Johnson company that makes blood glucose meters. WellDoc also raised an additional $7.5 million from Johnson & Johnson Innovation and other investors, bringing the company’s total funding in its most recent round to $29.5 million.  Existing investors include Samsung Ventures, Merck Global Health...
By Aditi Pai 10:04 am December 17, 2015
Baltimore, Maryland-based WellDoc has raised $22 million in a round led by Samsung Ventures and Merck Global Health Innovation (GHI) Fund with participation from Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners. The company will use the funds to focus on growing adoption of its flagship offering, BlueStar, an FDA-cleared mobile...
By Jonah Comstock 10:18 am August 19, 2015
WellDoc and Samsung will bring a new version of WellDoc's BlueStar mobile prescription therapy for diabetes to 300 Toronto citizens in partnership with the Ontario Telemedicine Network (OTN), a Canadian government-funded nonprofit. The new offering, BlueStar-S, will combine features of BlueStar and Samsung S Health. "Think of Samsung as a critical boost to what BlueStar already delivers," Anand...
By Jonah Comstock 11:15 am June 22, 2015
A recent column in the Harvard Business Review says that two kinds of business strategies will dominate in the gold rush-like healthcare economy of the future: Goldminers and Bartenders. "The Goldminer strategy will typically involve vertically integrated players (large institutions like insurers, hospitals, and physicians’ groups) creating medical value by better managing the health of the...
By Brian Dolan 09:16 am July 8, 2014
During a fireside chat at the annual Khosla Ventures CEO summit, investor Vinod Khosla talked to Google co-founders Larry Page and Sergey Brin about Google becoming a health company one day. As David Shaywitz wrote in a column for Forbes, Page and Brin see their company's health initiatives as "cool" projects, but they argue because of all the red tape in healthcare they are ultimately not...
By Brian Dolan 07:18 am March 13, 2014
Baltimore, Maryland-based WellDoc, one of the earliest and best known mobile health companies focused on diabetes management, has appointed Kevin McRaith as the company's new president. McRaith most recently served as VP of Sales & Marketing at Human Genome Sciences, and previously worked at Genentech, Abbott and Baxter. In this role McRaith will report to WellDoc CEO Ryan Sysko. WellDoc's...